Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors.
The company has developed a pipeline of highly promising novel drugs that aims to overcome the current limitations of cancer immunotherapy.
For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.
|Category||Program||Therapeutic Indication||Development stage|
|Target Discovery||Hit Optimization||Lead Optimization||Pre-clinical||IND||Clinical|
|Immune Checkpoint Antibody||MMB-101||Immuno Oncology|
|Program||Therapeutic Indication||Development stage|